By a News Reporter-Staff News Editor at Clinical Trials Week -- Nektar Therapeutics (Nasdaq: NKTR) announced its presence at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated data from clinical studies of NKTR-214. ASCO will take place June 2-6, 2017 in Chicago (see also Biotechnology Companies).
NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.
"We look forward to providing updates on NKTR-214, including the first data from the PIVOT trial evaluating NKTR-214 in combination with nivolumab, as well as updated data from the monotherapy trial of NKTR-214, including I-O naive RCC patients who received sequential checkpoint therapy following treatment with NKTR-214," said Mary Tagliaferri, M.D., Senior Vice President of Clinical Development at Nektar Therapeutics. "NKTR-214's unique mechanism which selectively increases tumor-killing TILs, combined with its favorable safety profile and clinical activity, support our combination trials of NKTR-214 with existing checkpoint inhibitors such as nivolumab and atezolizumab, as well as other immuno-oncology mechanisms in development."
NKTR-214 targets CD122 specific receptors found on the surface of cancer-fighting immune cells in order to stimulate their proliferation. In clinical and preclinical studies, treatment with NKTR-214 resulted in expansion of these cells and mobilization into the tumor micro-environment.1,2,3 NKTR-214 has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.
The abstracts published in advance of the ASCO meeting which were made available yesterday on the ASCO website at www.asco.org include preliminary data only as of February 7, 2017. Updated and additional patient data from these trials will be presented at ASCO.
Abstract 2545/Poster 37: "Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy."
Presenter: Chantale Bernatchez, Ph.D., The University of Texas MD Anderson Cancer Center
Poster Session: Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics
Date and Time: Monday, June 5, 2017 - 8:00 a.m. - 11:30 a.m. CDT
Keywords for this news article include: Pharmaceutical Companies, Cancer, Oncology, Nektar Therapeutics, Biotechnology Companies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC